Skip to main content
OpenTrials
Completed

NCT Number: NCT01715792

Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK

This study aims to assess the risk of solid organ transplant (SOT) rejection following vaccination with Pandemrix™ and/ or seasonal influenza vaccination.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

GSK Investigational Site

London, SW1W 9SZ, United Kingdom

About this study

Data on the safety of pandemic H1N1 vaccination in transplanted patients is relatively limited; to date, although some studies showed transient increases in alloreactivity, there is no evidence that H1N1 vaccines caused clinical rejection or organ dysfunction. In addition, studies have shown that influenza infection is a known independent risk factors for rejection. Considering that transplant recipients are a target population for immunisation with future pandemic vaccines, it is important to investigate the risk of rejection following vaccination in this patient population.

Using the self-controlled case series design that allows to control implicitly for potential confounding factors, this study aims at investigating the risk of solid organ transplant rejection (liver, kidney, lung, heart, pancreas) following vaccination with Pandemrix™ in the United Kingdom Clinical Practice Research Datalink GP Online Database (CPRD GOLD). Data from the Hospital Episodes Statistics database will also be used. The effect of seasonal influenza vaccination and of various infections including influenza H1N1 will also be explored.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject defined as acceptable in the CPRD GOLD.
  • Subject with at least one solid organ transplant rejection reported in the CPRD GOLD and/or HES during the overall study periods (01 September 2006 to 31 October 2010).

Exclusion criteria

  • Subject from HES matched to more than one subject in the CPRD GOLD.

Treatment and study plan

Data Collection

Other

Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.

Primary outcomes

  1. Assessment of the risk of solid organ transplant rejection (liver, kidney, lung, heart, pancreas).

    Time frame: Within one month after vaccination with Pandemrix™ (from 01 October 2009 to 31 October 2010).

    Assessed by case data collection from CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.

Secondary outcomes

  1. Assessment of the risk of solid organ transplant rejection (liver, kidney, lung, heart, pancreas).

    Time frame: Within two months after vaccination with Pandemrix™ ( from 01 October 2009 to 31 October 2010).

    Assessed by case data collection from CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in the United Kingdom

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Oct 29, 2012
Registry last updated
Feb 10, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.